Research Article
Efficacy of Abiraterone and Enzalutamide in Pre- and Postdocetaxel Castration-Resistant Prostate Cancer: A Trial-Level Meta-Analysis
Table 2
Baseline patient characteristics.
(a) Studies reporting median OS estimates |
| | AX | EX | | DA | DE | | Overall |
| Studies (count) | 3 | 2 | | 10 | 2 | | 17 | Sample Size | 649 | 923 | | 1920 | 993 | | 4485 | Race (count) | | | | | | | | White | 2 | 1 | | 8 | 2 | | 13 | Asian | 1 | 1 | | 2 | 0 | | 4 | Age (median) | 71.3 | 72.7 | | 70.7 | 71.0 | | 71.2 | Baseline PSA (median) | 184.0 | 32.7 | | 113.6 | 107.7 | | 107.7 | Gleason score ≥ 8 (proportion) | 42% | 52% | | 53% | 50% | | 39% | PSA decline ≥ 50% (proportion) | 34% | 77% | | 36% | 53% | | 48% |
|
|
(b) Studies reporting median PFS estimates |
| | AX | EX | | DA | DE | | Overall |
| Studies (count) | 3 | 4 | | 3 | 3 | | 13 | Sample size | 615 | 498 | | 1268 | 915 | | 3296 | Race (count) | | | | | | | | White | 3 | 3 | | 3 | 2 | | 11 | Asian | 1 | 1 | | 2 | 0 | | 2 | Age (median) | 70.6 | 71.2 | | 73.0 | 68.4 | | 70.6 | Baseline PSA (median) | 120.3 | 16.1 | | 32.5 | 64.0 | | 33.8 | Gleason score ≥ 8 (proportion) | 48% | 56% | | 51% | 52% | | 52% | PSA decline ≥ 50% (proportion) | 30% | 77% | | 38% | 53% | | 47% |
|
|
-tests with unequal variances values are shown for the comparisons between AX and EX and between DA and DE. Not enough information for the test.
|